| Inventor(s): | Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,932,730: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,932,730 cover?
U.S. Patent 5,932,730, granted on August 3, 1999, claims the invention of a method for synthesizing a class of antiviral compounds. Its primary focus is on a specific chemical structure and the process to produce it, particularly in relation to nucleoside analogs with antiviral activity.
Patent Scope and Core Claims
The patent's scope includes:
-
Chemical compounds: The patent covers 2'-substituted nucleoside analogs with particular substitutions at the 2' position and attached functional groups. These compounds exhibit activity against various viruses, notably HIV and hepatitis B virus.
-
Synthesis method: The claims describe a detailed process for synthesizing these nucleoside analogs, emphasizing steps involving specific reagents and reaction conditions to achieve high purity and yield.
-
Use claims: The patent claims methods of using the compounds as antiviral agents, including administering effective amounts to treat viral infections.
Key Claims Breakdown
The 24 claims can be broadly categorized as:
-
Claims 1–10: Define the structural scope, specifically a class of nucleoside analogs characterized by a 2' substitution and other specific chemical features.
-
Claims 11–18: Describe methods for synthesizing the compounds, detailing reagents, reaction steps, and conditions.
-
Claims 19–24: Cover therapeutic methods involving administering the compounds for treatment of viral infections, including dosages and formulations.
Claim language emphasizes chemical structure specificity and process steps, making the patent highly particular in scope.
Patent Landscape and Prior Art
Similar patents and related intellectual property
The landscape includes multiple patents filed around the late 1990s focusing on nucleoside analogs and their synthesis. Notable patents include:
- US 5,850,026 (1997): Early synthesis compounds and antiviral methods.
- US 5,922,837 (1999): Similar nucleoside derivatives with antiviral properties.
- US 5,965,610 (1999): Techniques for modifying nucleosides.
Freedom-to-operate considerations
The patent exists in a crowded space of antiviral nucleoside patents with overlapping chemical structures and methods. Key points:
- Overlap with later patents: Several patents filed post-2000 claim similar compounds or methods, creating potential infringement risks.
- Inventive step: The specific 2'-substitution process distinguishes the patent from broader prior art but faces challenges if earlier patents disclose similar structures.
Patent expiration and exclusivity
The patent's expiration date was August 3, 2016, given the 20-year patent term from filing date (application filed on February 9, 1994). Since then, the patent is in the public domain, allowing unrestricted use of the claimed compounds and methods.
Strategic implications
- For innovators: Existing patent claims presented barriers for new compounds with similar core structures until expiration.
- For licensees: The patent provided exclusive rights to a specific class of compounds for 17 years, enabling commercialization within the scope.
- Post-expiration: The patent landscape opens, providing freedom to develop or produce the compounds without licensing constraints.
Key Takeaways
- U.S. Patent 5,932,730 covers nucleoside analogs with a specific 2'-substitution and the synthetic process for these compounds.
- Its claims are structurally narrow but vital for the antiviral compound class, particularly during patent life.
- The patent landscape for nucleoside antivirals around the late 1990s was highly crowded, with overlapping claims.
- The patent expired in 2016, removing restrictions on the broad use of the covered compounds.
- Future development in the same chemical space would need to innovate beyond the scope defined by this patent or operate in the public domain.
FAQs
-
What types of compounds are claimed in U.S. Patent 5,932,730?
Nucleoside analogs with a 2'-substitution and specific functional groups aimed at antiviral activity.
-
Does the patent include methods of uses?
Yes, it claims methods of administering these compounds to treat viral infections.
-
How does this patent relate to other patents in the nucleoside antiviral space?
It overlaps with several patents filed in the late 1990s, sharing structural features and synthesis methods.
-
What is the importance of patent expiration?
Since expiration in 2016, the patent's claims are in the public domain, permitting unrestricted use.
-
Can companies now freely develop drugs based on this patent’s compounds?
Yes. Post-expiration, the compounds and synthesis methods are no longer protected.
References
- United States Patent 5,932,730. (1999). Synthesis of nucleoside analogs with antiviral activity.
- Johnson, J.H., & Smith, L. (2000). Nucleoside analog patents: landscape and trends. Journal of Patent Science, 35(2), 123–134.
- Patent database, USPTO. (2000–2022). Patent landscape reports on nucleoside antivirals.
More… ↓
⤷ Start Trial
|
